These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 26850287)

  • 1. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
    Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
    J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
    Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
    Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
    Lipsitz M; Delea TE; Guo A
    Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
    Matter-Walstra K; Ruhstaller T; Klingbiel D; Schwenkglenks M; Dedes KJ
    Breast Cancer Res Treat; 2016 Jul; 158(1):51-57. PubMed ID: 27277747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
    Ding H; Fang L; Xin W; Tong Y; Zhou Q; Huang P
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28675545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
    Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
    Karnon J; Delea T; Barghout V
    Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
    El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
    Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
    Benjamin L; Buthion V; Iskedjian M; Farah B; Rioufol C; Vidal-Trécan G
    J Med Econ; 2013; 16(1):96-107. PubMed ID: 22970840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
    Nuijten M; Meester L; Waibel F; Wait S
    Pharmacoeconomics; 1999 Oct; 16(4):379-97. PubMed ID: 10623366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
    Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
    Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.